Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free HEPA Stock Alerts

Hepion Pharmaceuticals (HEPA) Competitors

Hepion Pharmaceuticals logo
$0.10 +0.01 (+5.67%)
As of 05/14/2026 03:16 PM Eastern
Compare

HEPA vs. ELAB, QLGN, CANF, ADIL, and TRIB

Should you buy Hepion Pharmaceuticals stock or one of its competitors? MarketBeat compares Hepion Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hepion Pharmaceuticals include PMGC (ELAB), Qualigen Therapeutics (QLGN), Can-Fite BioPharma (CANF), Adial Pharmaceuticals (ADIL), and Trinity Biotech (TRIB). These companies are all part of the "pharmaceutical products" industry.

How does Hepion Pharmaceuticals compare to PMGC?

Hepion Pharmaceuticals (NASDAQ:HEPA) and PMGC (NASDAQ:ELAB) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

PMGC has higher revenue and earnings than Hepion Pharmaceuticals. PMGC is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hepion PharmaceuticalsN/AN/A-$48.93M-$72.15N/A
PMGC$590K4.05-$7.75M-$400.97N/A

Hepion Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, PMGC has a beta of -0.27, indicating that its stock price is 127% less volatile than the broader market.

In the previous week, PMGC had 9 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 9 mentions for PMGC and 0 mentions for Hepion Pharmaceuticals. PMGC's average media sentiment score of 0.77 beat Hepion Pharmaceuticals' score of 0.00 indicating that PMGC is being referred to more favorably in the news media.

Company Overall Sentiment
Hepion Pharmaceuticals Neutral
PMGC Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hepion Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
PMGC
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

PMGC's return on equity of -92.90% beat Hepion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hepion PharmaceuticalsN/A -812.56% -207.31%
PMGC N/A -92.90%-67.56%

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.2% of PMGC shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Comparatively, 0.0% of PMGC shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

PMGC beats Hepion Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Qualigen Therapeutics?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hepion PharmaceuticalsN/AN/A-$48.93M-$72.15N/A
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A

Hepion Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Hepion Pharmaceuticals' average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company Overall Sentiment
Hepion Pharmaceuticals Neutral
Qualigen Therapeutics Neutral

Qualigen Therapeutics' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hepion PharmaceuticalsN/A -812.56% -207.31%
Qualigen Therapeutics N/A N/A -202.16%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hepion Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Qualigen Therapeutics beats Hepion Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Can-Fite BioPharma?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Can-Fite BioPharma has higher revenue and earnings than Hepion Pharmaceuticals. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hepion PharmaceuticalsN/AN/A-$48.93M-$72.15N/A
Can-Fite BioPharma$405K5.64-$7.63M-$35.80N/A

Hepion Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Can-Fite BioPharma had 4 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 4 mentions for Can-Fite BioPharma and 0 mentions for Hepion Pharmaceuticals. Can-Fite BioPharma's average media sentiment score of 1.13 beat Hepion Pharmaceuticals' score of 0.00 indicating that Can-Fite BioPharma is being referred to more favorably in the news media.

Company Overall Sentiment
Hepion Pharmaceuticals Neutral
Can-Fite BioPharma Positive

Can-Fite BioPharma's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hepion PharmaceuticalsN/A -812.56% -207.31%
Can-Fite BioPharma N/A N/A N/A

Can-Fite BioPharma has a consensus target price of $6.00, suggesting a potential upside of 71.92%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than Hepion Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hepion Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

Can-Fite BioPharma beats Hepion Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Adial Pharmaceuticals?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hepion PharmaceuticalsN/AN/A-$48.93M-$72.15N/A
Adial PharmaceuticalsN/AN/A-$7.98M-$7.98N/A

Hepion Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Comparatively, 1.9% of Adial Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Adial Pharmaceuticals had 7 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 7 mentions for Adial Pharmaceuticals and 0 mentions for Hepion Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 1.42 beat Hepion Pharmaceuticals' score of 0.00 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Hepion Pharmaceuticals Neutral
Adial Pharmaceuticals Positive

Adial Pharmaceuticals' return on equity of -162.82% beat Hepion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hepion PharmaceuticalsN/A -812.56% -207.31%
Adial Pharmaceuticals N/A -162.82%-127.58%

Adial Pharmaceuticals has a consensus target price of $22.75, suggesting a potential upside of 1,572.79%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Adial Pharmaceuticals is more favorable than Hepion Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hepion Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Adial Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Adial Pharmaceuticals beats Hepion Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Trinity Biotech?

Trinity Biotech (NASDAQ:TRIB) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

79.0% of Trinity Biotech shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trinity Biotech
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Hepion Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Trinity Biotech had 3 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 3 mentions for Trinity Biotech and 0 mentions for Hepion Pharmaceuticals. Trinity Biotech's average media sentiment score of 0.96 beat Hepion Pharmaceuticals' score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Trinity Biotech Positive
Hepion Pharmaceuticals Neutral

Trinity Biotech has higher revenue and earnings than Hepion Pharmaceuticals. Trinity Biotech is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trinity Biotech$43.78M0.05-$37.38M-$9.40N/A
Hepion PharmaceuticalsN/AN/A-$48.93M-$72.15N/A

Hepion Pharmaceuticals has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%. Trinity Biotech's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Trinity Biotech-85.36% N/A -36.62%
Hepion Pharmaceuticals N/A -812.56%-207.31%

Summary

Trinity Biotech beats Hepion Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

Get Hepion Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HEPA vs. The Competition

Export
MetricHepion PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$491K$935.60M$6.34B$12.37B
Dividend YieldN/A4.84%2.80%5.35%
P/E Ratio-0.021.4820.6625.63
Price / SalesN/A115.81547.7676.59
Price / CashN/A20.0743.2656.33
Price / Book0.078.119.886.97
Net Income-$48.93M-$3.91M$3.55B$333.62M
7 Day PerformanceN/A9.43%1.69%1.09%
1 Month PerformanceN/A76.62%0.48%3.08%
1 Year PerformanceN/A140.55%39.39%35.68%

Hepion Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HEPA
Hepion Pharmaceuticals
N/A$0.10
+5.7%		N/A-21.8%$491KN/AN/A20
ELAB
PMGC
0.8817 of 5 stars		$2.08
-5.3%		N/A-99.0%$2.42M$590KN/A18
QLGN
Qualigen Therapeutics
N/A$1.42
+0.7%		N/A-64.3%$2.41MN/AN/A50
CANF
Can-Fite BioPharma
2.6563 of 5 stars		$3.51
+0.2%		$65.00
+1,753.4%		-83.1%$2.30M$405KN/A8
ADIL
Adial Pharmaceuticals
2.5692 of 5 stars		$1.60
-0.3%		$22.75
+1,326.3%		-91.6%$2.28MN/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:HEPA) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel